1-naphthoate | 145117-62-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-naphthoate
• 英文别名: naphthalene-1-carboxylate
• CAS: 145117-62-0
• 化学式: C₁₁H₇O₂
• 分子量: 171.175
• InChiKey: LNETULKMXZVUST-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-naphthoate 在 phosphate buffer 、 Pseudomonas sp. TA-2 作用下， 生成 (1R,2S)-1,2-Dihydroxy-1,2-dihydro-naphthalene-1-carboxylic acid
  参考文献：
  名称：

  Conversion of Naphthoates tocis-Dihydrodiols by Naphthalenesulfonate-assimilatingPseudomonassp. TA-2

  摘要：

  发现一种萘磺酸盐同化细菌——假单胞菌属TA-2可将2-萘酸盐转化为顺式-1,2-二羟基-1,2-二氢萘-2-羧酸酯（DDN2C）和顺式-1,2-二羟基-1,2-二氢萘-3-羧酸酯（DDN3C），并将1-萘酸盐转化为反式-1,2-二羟基-1,2-二氢萘-1-羧酸酯（DDN1C）。有人提出，萘酸盐的转化是由一种具有弱位选择性二氧戊环酶完成的。

  DOI：

  10.1271/bbb.60.883
• 作为产物：
  描述：

  以 重水 为溶剂， 生成 三氢化钐 、 1-naphthoate
  参考文献：
  名称：

  Gruzdev, V. P.; Ermolaev, V. L., Zhurnal Neorganicheskoi Khimii, 1978, vol. 23, p. 673 - 677

  摘要：

  DOI：

文献信息

• Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05635477A1

  公开（公告）日：1997-06-03

  This invention relates to novel cyclic compounds containing carbocyclic ring systems useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, with or without other therapeutic agents, and to methods of using these compounds, with or without other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. This invention also relates to methods of using the cyclic compounds of the invention in combination with anti-coagulants such as warfarin or heparin, or additional anti-platelet agents such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors such as boropeptides, hirudin or argatroban, or thrombolytic agents such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, for the treatment of thromboembolic disorders. A representative compound of the invention is cyclo(D-Val-(.sup..alpha. N-methyl Arg)-Gly-Asp-(3-aminomethylbenzoic acid).

  本发明涉及新型含环状化合物的抗血小板糖蛋白IIb/IIIa复合物拮抗剂，这些化合物含有碳环状系统，可用于制备药物组合物，包括这些环状化合物，与或不含其他治疗剂，以及使用这些化合物，与或不含其他治疗剂，用于抑制血小板聚集，作为溶栓剂和/或用于治疗其他血栓栓塞性疾病的方法。本发明还涉及使用本发明的环状化合物与抗凝剂（如华法林或肝素）或其他抗血小板剂（如阿司匹林、吡罗昔康或替克洛匹定）或凝血酶抑制剂（如硼肽、酶素或阿加曲班）或溶栓剂（如组织型纤溶酶原激活剂、安斯特雷普拉斯、尿激酶或链激酶）或其组合物，用于治疗血栓栓塞性疾病的方法。本发明的代表性化合物是环状D-Val-(.sup..alpha. N-甲基Arg)-Gly-Asp-(3-氨甲基苯甲酸)。
• photoresist composition
  申请人：Allen David Robert

  公开号：US20060128914A1

  公开（公告）日：2006-06-15

  A photoresist composition is provided that includes a polymer having at least one acrylate or methacrylate monomer having a formula where R 1 represents hydrogen (H), a linear or branched alkyl group of 1 to 20 carbons, or a semi- or perfluorinated linear or branched alkyl group of 1 to 20 carbons; and where R 2 represents an unsubstituted aliphatic group or a substituted aliphatic group having zero or one trifluoromethyl (CF 3 ) group attached to each carbon of the substituted aliphatic group, or a substituted or unsubstituted aromatic group; and where R 3 represents hydrogen (H), methyl (CH 3 ), trifluoromethyl (CF 3 ), difluoromethyl (CHF 2 ), fluoromethyl (CH 2 F), or a semi- or perfluorinated aliphatic chain; and where R 4 represents trifluoromethyl (CF 3 ), difluoromethyl (CHF 2 ), fluoromethyl (CH 2 F), or a semi- or perfluorinated substituted or unsubstituted aliphatic group. A method of patterning a substrate using the photoresist composition is also provided herein.

  提供了一种光阻组合物，其中包括聚合物，该聚合物具有至少一种丙烯酸酯或甲基丙烯酸酯单体，其具有以下结构式：其中R1代表氢（H）、具有1到20个碳的线性或支链烷基，或具有1到20个碳的半氟或全氟化的线性或支链烷基；其中R2代表未取代的脂肪族基或取代的脂肪族基，该脂肪族基每个碳上附有零或一个三氟甲基（CF3）基团，或取代或未取代的芳香族基；其中R3代表氢（H）、甲基（CH3）、三氟甲基（CF3）、二氟甲基（CHF2）、氟甲基（CH2F）或半氟或全氟化的脂肪族链；其中R4代表三氟甲基（CF3）、二氟甲基（CHF2）、氟甲基（CH2F）或半氟或全氟化的取代或未取代的脂肪族基。本文还提供了使用该光阻组合物进行图案化基板的方法。
• Photoresist composition
  申请人：International Business Machines Corporation

  公开号：US20030224283A1

  公开（公告）日：2003-12-04

  A photoresist composition is provided that includes a polymer having at least one acrylate or methacrylate monomer having a formula 1 where R 1 represents hydrogen (H), a linear or branched alkyl group of 1 to 20 carbons, or a semi- or perfluorinated linear or branched alkyl group of 1 to 20 carbons; and where R 2 represents an unsubstituted aliphatic group or a substituted aliphatic group having zero or one trifluoromethyl (CF 3 ) group attached to each carbon of the substituted aliphatic group, or a substituted or unsubstituted aromatic group; and where R 3 represents hydrogen (H), methyl (CH 3 ), trifluoromethyl (CF 3 ), difluoromethyl (CHF 2 ), fluoromethyl (CH 2 F), or a semi- or perfluorinated aliphatic chain; and where R 4 represents trifluoromethyl (CF 3 ), difluoromethyl (CHF 2 ), fluoromethyl (CH 2 F), or a semi- or perfluorinated substituted or unsubstituted aliphatic group. A method of patterning a substrate using the photoresist composition is also provided herein.

  提供一种光阻组合物，包括具有至少一个丙烯酸酯或甲基丙烯酸酯单体的聚合物，其具有公式1，其中R1表示氢（H），具有1到20个碳的线性或支链烷基，或具有1到20个碳的半氟或全氟线性或支链烷基；R2表示未取代的脂肪基或取代的脂肪基，其在每个碳原子上附有零个或一个三氟甲基（CF3）基团，或取代或未取代的芳香族基；R3表示氢（H），甲基（CH3），三氟甲基（CF3），二氟甲基（CHF2），氟甲基（CH2F）或半氟或全氟脂肪链；R4表示三氟甲基（CF3），二氟甲基（CHF2），氟甲基（CH2F）或半氟或全氟取代或未取代的脂肪基。本文还提供了一种使用该光阻组合物进行图案化基板的方法。
• N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
  申请人：Astrazeneca AB

  公开号：US06403601B1

  公开（公告）日：2002-06-11

  Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

  式(I)的化合物，其中R2是5,6,7,8-四氢萘-1-基基团，该基团可以被取代（其余在此定义的基团），以及含有该化合物的制药组合物和使用该化合物治疗拮抗NK1和/或NK2受体有益的疾病的方法。
• Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents
  申请人：DuPont Pharmaceuticals Company

  公开号：US06022523A1

  公开（公告）日：2000-02-08

  This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

  本发明提供了新型放射性药物，它们是放射性标记的环状化合物，包含碳环或杂环环系统，可作为血小板糖蛋白IIb/IIIa复合物的拮抗剂；本发明还提供了使用该放射性药物作为诊断动脉和静脉血栓的成像剂的方法；提供了制备该放射性药物的新型试剂；以及包含该试剂的试剂盒。